APO Research
Talk to an analyst

APO RESEARCH · REPORT

DTaP and Tdap Vaccines

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global DTaP and Tdap Vaccines Market Analysis and Forecast 2026-2032

19 December 2025191 pages

Choose your research edition.

Industry ResearchDTaP and Tdap Vaccines Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal DTaP and Tdap Vaccines Industry Growth and Trends Forecast to 2032108 pages · $3,450 USDMarket StructureGlobal DTaP and Tdap Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal DTaP and Tdap Vaccines Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal DTaP and Tdap Vaccines Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global DTaP and Tdap Vaccines market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for DTaP and Tdap Vaccines is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for DTaP and Tdap Vaccines is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for DTaP and Tdap Vaccines is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for DTaP and Tdap Vaccines is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of DTaP and Tdap Vaccines include Johnson & Johnson, Novartis AG, Lanzhou Institute of Biological Products Co., Ltd, Pfizer Inc, GlaxoSmithKline, AstraZeneca, Seqirus, Sanofi Pasteur and Protein Sciences Corporation, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for DTaP and Tdap Vaccines, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of DTaP and Tdap Vaccines, also provides the sales of main regions and countries. Of the upcoming market potential for DTaP and Tdap Vaccines, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the DTaP and Tdap Vaccines sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global DTaP and Tdap Vaccines market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for DTaP and Tdap Vaccines sales, projected growth trends, production technology, application and end-user industry.

DTaP and Tdap Vaccines Segment by Company

Johnson & Johnson

Novartis AG

Lanzhou Institute of Biological Products Co., Ltd

Pfizer Inc

GlaxoSmithKline

AstraZeneca

Seqirus

Sanofi Pasteur

Protein Sciences Corporation

Merck Sharp & Dohme Corp

Emergent BioSolutions Inc

Astellas Pharma US, Inc

DTaP and Tdap Vaccines Segment by Type

Tdap

DTaP

Td

DTaP and Tdap Vaccines Segment by Application

Adult

Pediatric

DTaP and Tdap Vaccines Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global DTaP and Tdap Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of DTaP and Tdap Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of DTaP and Tdap Vaccines.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of DTaP and Tdap Vaccines in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of DTaP and Tdap Vaccines manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, DTaP and Tdap Vaccines sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global DTaP and Tdap Vaccines Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Tdap Major Manufacturers Table 3. DTaP Major Manufacturers Table 4. Td Major Manufacturers Table 5. Global DTaP and Tdap Vaccines Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Adult Major Manufacturers Table 7. Pediatric Major Manufacturers Table 8. DTaP and Tdap Vaccines Industry Trends Table 9. DTaP and Tdap Vaccines Industry Drivers Table 10. DTaP and Tdap Vaccines Industry Opportunities and Challenges Table 11. DTaP and Tdap Vaccines Industry Restraints Table 12. Global DTaP and Tdap Vaccines Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 13. Global DTaP and Tdap Vaccines Revenue by Region (2021-2026) & (US$ Million) Table 14. Global DTaP and Tdap Vaccines Revenue by Region (2027-2032) & (US$ Million) Table 15. Global DTaP and Tdap Vaccines Revenue Market Share by Region (2021-2026) Table 16. Global DTaP and Tdap Vaccines Revenue Market Share by Region (2027-2032) Table 17. Global DTaP and Tdap Vaccines Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (W Units) Table 18. Global DTaP and Tdap Vaccines Sales by Region (2021-2026) & (W Units) Table 19. Global DTaP and Tdap Vaccines Sales by Region (2027-2032) & (W Units) Table 20. Global DTaP and Tdap Vaccines Sales Market Share by Region (2021-2026) Table 21. Global DTaP and Tdap Vaccines Sales Market Share by Region (2027-2032) Table 22. Global DTaP and Tdap Vaccines Revenue by Manufacturers (US$ Million) & (2021-2026) Table 23. Global DTaP and Tdap Vaccines Revenue Market Share by Manufacturers (2021-2026) Table 24. Global DTaP and Tdap Vaccines Sales by Manufacturers (US$ Million) & (2021-2026) Table 25. Global DTaP and Tdap Vaccines Sales Market Share by Manufacturers (2021-2026) Table 26. Global DTaP and Tdap Vaccines Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 27. Global DTaP and Tdap Vaccines Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 28. Global DTaP and Tdap Vaccines Key Manufacturers Manufacturing Sites & Headquarters Table 29. Global DTaP and Tdap Vaccines Manufacturers, Product Type & Application Table 30. Global DTaP and Tdap Vaccines Manufacturers' Establishment Date Table 31. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 32. Global DTaP and Tdap Vaccines by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 33. Global DTaP and Tdap Vaccines Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global DTaP and Tdap Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 35. Global DTaP and Tdap Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 36. Global DTaP and Tdap Vaccines Revenue Market Share by Type (2021-2026) Table 37. Global DTaP and Tdap Vaccines Revenue Market Share by Type (2027-2032) Table 38. Global DTaP and Tdap Vaccines Sales by Type 2021 VS 2025 VS 2032 (W Units) Table 39. Global DTaP and Tdap Vaccines Sales by Type (2021-2026) & (W Units) Table 40. Global DTaP and Tdap Vaccines Sales by Type (2027-2032) & (W Units) Table 41. Global DTaP and Tdap Vaccines Sales Market Share by Type (2021-2026) Table 42. Global DTaP and Tdap Vaccines Sales Market Share by Type (2027-2032) Table 43. Global DTaP and Tdap Vaccines Price by Type (2021-2026) & (US$/Unit) Table 44. Global DTaP and Tdap Vaccines Price by Type (2027-2032) & (US$/Unit) Table 45. Global DTaP and Tdap Vaccines Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 46. Global DTaP and Tdap Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 47. Global DTaP and Tdap Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 48. Global DTaP and Tdap Vaccines Revenue Market Share by Application (2021-2026) Table 49. Global DTaP and Tdap Vaccines Revenue Market Share by Application (2027-2032) Table 50. Global DTaP and Tdap Vaccines Sales by Application 2021 VS 2025 VS 2032 (W Units) Table 51. Global DTaP and Tdap Vaccines Sales by Application (2021-2026) & (W Units) Table 52. Global DTaP and Tdap Vaccines Sales by Application (2027-2032) & (W Units) Table 53. Global DTaP and Tdap Vaccines Sales Market Share by Application (2021-2026) Table 54. Global DTaP and Tdap Vaccines Sales Market Share by Application (2027-2032) Table 55. Global DTaP and Tdap Vaccines Price by Application (2021-2026) & (US$/Unit) Table 56. Global DTaP and Tdap Vaccines Price by Application (2027-2032) & (US$/Unit) Table 57. Johnson & Johnson Company Information Table 58. Johnson & Johnson Business Overview Table 59. Johnson & Johnson DTaP and Tdap Vaccines Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 60. Johnson & Johnson DTaP and Tdap Vaccines Product Portfolio Table 61. Johnson & Johnson Recent Development Table 62. Novartis AG Company Information Table 63. Novartis AG Business Overview Table 64. Novartis AG DTaP and Tdap Vaccines Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 65. Novartis AG DTaP and Tdap Vaccines Product Portfolio Table 66. Novartis AG Recent Development Table 67. Lanzhou Institute of Biological Products Co., Ltd Company Information Table 68. Lanzhou Institute of Biological Products Co., Ltd Business Overview Table 69. Lanzhou Institute of Biological Products Co., Ltd DTaP and Tdap Vaccines Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 70. Lanzhou Institute of Biological Products Co., Ltd DTaP and Tdap Vaccines Product Portfolio Table 71. Lanzhou Institute of Biological Products Co., Ltd Recent Development Table 72. Pfizer Inc Company Information Table 73. Pfizer Inc Business Overview Table 74. Pfizer Inc DTaP and Tdap Vaccines Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. Pfizer Inc DTaP and Tdap Vaccines Product Portfolio Table 76. Pfizer Inc Recent Development Table 77. GlaxoSmithKline Company Information Table 78. GlaxoSmithKline Business Overview Table 79. GlaxoSmithKline DTaP and Tdap Vaccines Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. GlaxoSmithKline DTaP and Tdap Vaccines Product Portfolio Table 81. GlaxoSmithKline Recent Development Table 82. AstraZeneca Company Information Table 83. AstraZeneca Business Overview Table 84. AstraZeneca DTaP and Tdap Vaccines Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. AstraZeneca DTaP and Tdap Vaccines Product Portfolio Table 86. AstraZeneca Recent Development Table 87. Seqirus Company Information Table 88. Seqirus Business Overview Table 89. Seqirus DTaP and Tdap Vaccines Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Seqirus DTaP and Tdap Vaccines Product Portfolio Table 91. Seqirus Recent Development Table 92. Sanofi Pasteur Company Information Table 93. Sanofi Pasteur Business Overview Table 94. Sanofi Pasteur DTaP and Tdap Vaccines Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Sanofi Pasteur DTaP and Tdap Vaccines Product Portfolio Table 96. Sanofi Pasteur Recent Development Table 97. Protein Sciences Corporation Company Information Table 98. Protein Sciences Corporation Business Overview Table 99. Protein Sciences Corporation DTaP and Tdap Vaccines Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Protein Sciences Corporation DTaP and Tdap Vaccines Product Portfolio Table 101. Protein Sciences Corporation Recent Development Table 102. Merck Sharp & Dohme Corp Company Information Table 103. Merck Sharp & Dohme Corp Business Overview Table 104. Merck Sharp & Dohme Corp DTaP and Tdap Vaccines Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Merck Sharp & Dohme Corp DTaP and Tdap Vaccines Product Portfolio Table 106. Merck Sharp & Dohme Corp Recent Development Table 107. Emergent BioSolutions Inc Company Information Table 108. Emergent BioSolutions Inc Business Overview Table 109. Emergent BioSolutions Inc DTaP and Tdap Vaccines Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. Emergent BioSolutions Inc DTaP and Tdap Vaccines Product Portfolio Table 111. Emergent BioSolutions Inc Recent Development Table 112. Astellas Pharma US, Inc Company Information Table 113. Astellas Pharma US, Inc Business Overview Table 114. Astellas Pharma US, Inc DTaP and Tdap Vaccines Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. Astellas Pharma US, Inc DTaP and Tdap Vaccines Product Portfolio Table 116. Astellas Pharma US, Inc Recent Development Table 117. North America DTaP and Tdap Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 118. North America DTaP and Tdap Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 119. North America DTaP and Tdap Vaccines Sales by Type (2021-2026) & (W Units) Table 120. North America DTaP and Tdap Vaccines Sales by Type (2027-2032) & (W Units) Table 121. North America DTaP and Tdap Vaccines Sales Price by Type (2021-2026) & (US$/Unit) Table 122. North America DTaP and Tdap Vaccines Sales Price by Type (2027-2032) & (US$/Unit) Table 123. North America DTaP and Tdap Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 124. North America DTaP and Tdap Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 125. North America DTaP and Tdap Vaccines Sales by Application (2021-2026) & (W Units) Table 126. North America DTaP and Tdap Vaccines Sales by Application (2027-2032) & (W Units) Table 127. North America DTaP and Tdap Vaccines Sales Price by Application (2021-2026) & (US$/Unit) Table 128. North America DTaP and Tdap Vaccines Sales Price by Application (2027-2032) & (US$/Unit) Table 129. North America DTaP and Tdap Vaccines Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 130. North America DTaP and Tdap Vaccines Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 131. North America DTaP and Tdap Vaccines Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 132. North America DTaP and Tdap Vaccines Sales by Country (2021 VS 2025 VS 2032) & (W Units) Table 133. North America DTaP and Tdap Vaccines Sales by Country (2021-2026) & (W Units) Table 134. North America DTaP and Tdap Vaccines Sales by Country (2027-2032) & (W Units) Table 135. North America DTaP and Tdap Vaccines Sales Price by Country (2021-2026) & (US$/Unit) Table 136. North America DTaP and Tdap Vaccines Sales Price by Country (2027-2032) & (US$/Unit) Table 137. United States DTaP and Tdap Vaccines Revenue (2021-2032) & (US$ Million) Table 138. Canada DTaP and Tdap Vaccines Revenue (2021-2032) & (US$ Million) Table 139. Europe DTaP and Tdap Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 140. Europe DTaP and Tdap Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 141. Europe DTaP and Tdap Vaccines Sales by Type (2021-2026) & (W Units) Table 142. Europe DTaP and Tdap Vaccines Sales by Type (2027-2032) & (W Units) Table 143. Europe DTaP and Tdap Vaccines Sales Price by Type (2021-2026) & (US$/Unit) Table 144. Europe DTaP and Tdap Vaccines Sales Price by Type (2027-2032) & (US$/Unit) Table 145. Europe DTaP and Tdap Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 146. Europe DTaP and Tdap Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 147. Europe DTaP and Tdap Vaccines Sales by Application (2021-2026) & (W Units) Table 148. Europe DTaP and Tdap Vaccines Sales by Application (2027-2032) & (W Units) Table 149. Europe DTaP and Tdap Vaccines Sales Price by Application (2021-2026) & (US$/Unit) Table 150. Europe DTaP and Tdap Vaccines Sales Price by Application (2027-2032) & (US$/Unit) Table 151. Europe DTaP and Tdap Vaccines Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 152. Europe DTaP and Tdap Vaccines Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 153. Europe DTaP and Tdap Vaccines Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 154. Europe DTaP and Tdap Vaccines Sales by Country (2021 VS 2025 VS 2032) & (W Units) Table 155. Europe DTaP and Tdap Vaccines Sales by Country (2021-2026) & (W Units) Table 156. Europe DTaP and Tdap Vaccines Sales by Country (2027-2032) & (W Units) Table 157. Europe DTaP and Tdap Vaccines Sales Price by Country (2021-2026) & (US$/Unit) Table 158. Europe DTaP and Tdap Vaccines Sales Price by Country (2027-2032) & (US$/Unit) Table 159. Germany DTaP and Tdap Vaccines Revenue (2021-2032) & (US$ Million) Table 160. France DTaP and Tdap Vaccines Revenue (2021-2032) & (US$ Million) Table 161. U.K. DTaP and Tdap Vaccines Revenue (2021-2032) & (US$ Million) Table 162. Italy DTaP and Tdap Vaccines Revenue (2021-2032) & (US$ Million) Table 163. Netherlands DTaP and Tdap Vaccines Revenue (2021-2032) & (US$ Million) Table 164. Nordic Countries DTaP and Tdap Vaccines Revenue (2021-2032) & (US$ Million) Table 165. China DTaP and Tdap Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 166. China DTaP and Tdap Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 167. China DTaP and Tdap Vaccines Sales by Type (2021-2026) & (W Units) Table 168. China DTaP and Tdap Vaccines Sales by Type (2027-2032) & (W Units) Table 169. China DTaP and Tdap Vaccines Sales Price by Type (2021-2026) & (US$/Unit) Table 170. China DTaP and Tdap Vaccines Sales Price by Type (2027-2032) & (US$/Unit) Table 171. China DTaP and Tdap Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 172. China DTaP and Tdap Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 173. China DTaP and Tdap Vaccines Sales by Application (2021-2026) & (W Units) Table 174. China DTaP and Tdap Vaccines Sales by Application (2027-2032) & (W Units) Table 175. China DTaP and Tdap Vaccines Sales Price by Application (2021-2026) & (US$/Unit) Table 176. China DTaP and Tdap Vaccines Sales Price by Application (2027-2032) & (US$/Unit) Table 177. Asia DTaP and Tdap Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 178. Asia DTaP and Tdap Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 179. Asia DTaP and Tdap Vaccines Sales by Type (2021-2026) & (W Units) Table 180. Asia DTaP and Tdap Vaccines Sales by Type (2027-2032) & (W Units) Table 181. Asia DTaP and Tdap Vaccines Sales Price by Type (2021-2026) & (US$/Unit) Table 182. Asia DTaP and Tdap Vaccines Sales Price by Type (2027-2032) & (US$/Unit) Table 183. Asia DTaP and Tdap Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 184. Asia DTaP and Tdap Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 185. Asia DTaP and Tdap Vaccines Sales by Application (2021-2026) & (W Units) Table 186. Asia DTaP and Tdap Vaccines Sales by Application (2027-2032) & (W Units) Table 187. Asia DTaP and Tdap Vaccines Sales Price by Application (2021-2026) & (US$/Unit) Table 188. Asia DTaP and Tdap Vaccines Sales Price by Application (2027-2032) & (US$/Unit) Table 189. Asia DTaP and Tdap Vaccines Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 190. Asia DTaP and Tdap Vaccines Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 191. Asia DTaP and Tdap Vaccines Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 192. Asia DTaP and Tdap Vaccines Sales by Country (2021 VS 2025 VS 2032) & (W Units) Table 193. Asia DTaP and Tdap Vaccines Sales by Country (2021-2026) & (W Units) Table 194. Asia DTaP and Tdap Vaccines Sales by Country (2027-2032) & (W Units) Table 195. Asia DTaP and Tdap Vaccines Sales Price by Country (2021-2026) & (US$/Unit) Table 196. Asia DTaP and Tdap Vaccines Sales Price by Country (2027-2032) & (US$/Unit) Table 197. Japan DTaP and Tdap Vaccines Revenue (2021-2032) & (US$ Million) Table 198. South Korea DTaP and Tdap Vaccines Revenue (2021-2032) & (US$ Million) Table 199. India DTaP and Tdap Vaccines Revenue (2021-2032) & (US$ Million) Table 200. Australia DTaP and Tdap Vaccines Revenue (2021-2032) & (US$ Million) Table 201. China Taiwan DTaP and Tdap Vaccines Revenue (2021-2032) & (US$ Million) Table 202. Southeast Asia DTaP and Tdap Vaccines Revenue (2021-2032) & (US$ Million) Table 203. SAMEA DTaP and Tdap Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 204. SAMEA DTaP and Tdap Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 205. SAMEA DTaP and Tdap Vaccines Sales by Type (2021-2026) & (W Units) Table 206. SAMEA DTaP and Tdap Vaccines Sales by Type (2027-2032) & (W Units) Table 207. SAMEA DTaP and Tdap Vaccines Sales Price by Type (2021-2026) & (US$/Unit) Table 208. SAMEA DTaP and Tdap Vaccines Sales Price by Type (2027-2032) & (US$/Unit) Table 209. SAMEA DTaP and Tdap Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 210. SAMEA DTaP and Tdap Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 211. SAMEA DTaP and Tdap Vaccines Sales by Application (2021-2026) & (W Units) Table 212. SAMEA DTaP and Tdap Vaccines Sales by Application (2027-2032) & (W Units) Table 213. SAMEA DTaP and Tdap Vaccines Sales Price by Application (2021-2026) & (US$/Unit) Table 214. SAMEA DTaP and Tdap Vaccines Sales Price by Application (2027-2032) & (US$/Unit) Table 215. SAMEA DTaP and Tdap Vaccines Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 216. SAMEA DTaP and Tdap Vaccines Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 217. SAMEA DTaP and Tdap Vaccines Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 218. SAMEA DTaP and Tdap Vaccines Sales by Country (2021 VS 2025 VS 2032) & (W Units) Table 219. SAMEA DTaP and Tdap Vaccines Sales by Country (2021-2026) & (W Units) Table 220. SAMEA DTaP and Tdap Vaccines Sales by Country (2027-2032) & (W Units) Table 221. SAMEA DTaP and Tdap Vaccines Sales Price by Country (2021-2026) & (US$/Unit) Table 222. SAMEA DTaP and Tdap Vaccines Sales Price by Country (2027-2032) & (US$/Unit) Table 223. Brazil DTaP and Tdap Vaccines Revenue (2021-2032) & (US$ Million) Table 224. Argentina DTaP and Tdap Vaccines Revenue (2021-2032) & (US$ Million) Table 225. Chile DTaP and Tdap Vaccines Revenue (2021-2032) & (US$ Million) Table 226. Colombia DTaP and Tdap Vaccines Revenue (2021-2032) & (US$ Million) Table 227. Peru DTaP and Tdap Vaccines Revenue (2021-2032) & (US$ Million) Table 228. Saudi Arabia DTaP and Tdap Vaccines Revenue (2021-2032) & (US$ Million) Table 229. Israel DTaP and Tdap Vaccines Revenue (2021-2032) & (US$ Million) Table 230. UAE DTaP and Tdap Vaccines Revenue (2021-2032) & (US$ Million) Table 231. Turkey DTaP and Tdap Vaccines Revenue (2021-2032) & (US$ Million) Table 232. Iran DTaP and Tdap Vaccines Revenue (2021-2032) & (US$ Million) Table 233. Egypt DTaP and Tdap Vaccines Revenue (2021-2032) & (US$ Million) Table 234. Key Raw Materials Table 235. Raw Materials Key Suppliers Table 236. DTaP and Tdap Vaccines Distributors List Table 237. DTaP and Tdap Vaccines Customers List Table 238. Research Programs/Design for This Report Table 239. Authors List of This Report Table 240. Secondary Sources Table 241. Primary Sources List of Figures Figure 1. DTaP and Tdap Vaccines Image Figure 2. Global DTaP and Tdap Vaccines Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global DTaP and Tdap Vaccines Market Size Share 2021 VS 2025 VS 2032 Figure 4. Tdap Image Figure 5. DTaP Image Figure 6. Td Image Figure 7. Global DTaP and Tdap Vaccines Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global DTaP and Tdap Vaccines Market Size Share 2021 VS 2025 VS 2032 Figure 9. Adult Image Figure 10. Pediatric Image Figure 11. Global DTaP and Tdap Vaccines Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global DTaP and Tdap Vaccines Revenue (2021-2032) & (US$ Million) Figure 13. Global DTaP and Tdap Vaccines Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 14. Global DTaP and Tdap Vaccines Revenue Market Share by Region: 2025 Versus 2032 Figure 15. Global DTaP and Tdap Vaccines Revenue Market Share by Region (2021-2032) Figure 16. Global DTaP and Tdap Vaccines Sales (2021-2032) & (W Units) Figure 17. Global DTaP and Tdap Vaccines Sales by Region: 2021 VS 2025 VS 2032 (W Units) Figure 18. Global DTaP and Tdap Vaccines Sales Market Share by Region (2021-2032) Figure 19. US & Canada & Mexico DTaP and Tdap Vaccines Sales YoY (2021-2032) & (W Units) Figure 20. Europe DTaP and Tdap Vaccines Sales YoY (2021-2032) & (W Units) Figure 21. China DTaP and Tdap Vaccines Sales YoY (2021-2032) & (W Units) Figure 22. Asia (Excluding China) DTaP and Tdap Vaccines Sales YoY (2021-2032) & (W Units) Figure 23. South America, Middle East and Africa DTaP and Tdap Vaccines Sales YoY (2021-2032) & (W Units) Figure 24. Global DTaP and Tdap Vaccines Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 25. Global DTaP and Tdap Vaccines Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 26. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Global DTaP and Tdap Vaccines Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global DTaP and Tdap Vaccines Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 29. Global DTaP and Tdap Vaccines Revenue Market Share by Type (2021-2032) Figure 30. Global DTaP and Tdap Vaccines Sales by Type (2021 VS 2025 VS 2032) & (W Units) Figure 31. Global DTaP and Tdap Vaccines Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 32. Global DTaP and Tdap Vaccines Sales Market Share by Type (2021-2032) Figure 33. Global DTaP and Tdap Vaccines Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 34. Global DTaP and Tdap Vaccines Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 35. Global DTaP and Tdap Vaccines Revenue Market Share by Application (2021-2032) Figure 36. Global DTaP and Tdap Vaccines Sales by Application (2021 VS 2025 VS 2032) & (W Units) Figure 37. Global DTaP and Tdap Vaccines Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 38. Global DTaP and Tdap Vaccines Sales Market Share by Application (2021-2032) Figure 39. North America DTaP and Tdap Vaccines Revenue Share by Type (2021-2032) Figure 40. North America DTaP and Tdap Vaccines Sales Share by Type (2021-2032) Figure 41. North America DTaP and Tdap Vaccines Revenue Share by Application (2021-2032) Figure 42. North America DTaP and Tdap Vaccines Sales Share by Application (2021-2032) Figure 43. North America DTaP and Tdap Vaccines Revenue Share by Country (2021-2032) Figure 44. North America DTaP and Tdap Vaccines Sales Share by Country (2021-2032) Figure 45. Europe DTaP and Tdap Vaccines Revenue Share by Type (2021-2032) Figure 46. Europe DTaP and Tdap Vaccines Sales Share by Type (2021-2032) Figure 47. Europe DTaP and Tdap Vaccines Revenue Share by Application (2021-2032) Figure 48. Europe DTaP and Tdap Vaccines Sales Share by Application (2021-2032) Figure 49. Europe DTaP and Tdap Vaccines Revenue Share by Country (2021-2032) Figure 50. Europe DTaP and Tdap Vaccines Sales Share by Country (2021-2032) Figure 51. China DTaP and Tdap Vaccines Revenue Share by Type (2021-2032) Figure 52. China DTaP and Tdap Vaccines Sales Share by Type (2021-2032) Figure 53. China DTaP and Tdap Vaccines Revenue Share by Application (2021-2032) Figure 54. China DTaP and Tdap Vaccines Sales Share by Application (2021-2032) Figure 55. Asia DTaP and Tdap Vaccines Revenue Share by Type (2021-2032) Figure 56. Asia DTaP and Tdap Vaccines Sales Share by Type (2021-2032) Figure 57. Asia DTaP and Tdap Vaccines Revenue Share by Application (2021-2032) Figure 58. Asia DTaP and Tdap Vaccines Sales Share by Application (2021-2032) Figure 59. Asia DTaP and Tdap Vaccines Revenue Share by Country (2021-2032) Figure 60. Asia DTaP and Tdap Vaccines Sales Share by Country (2021-2032) Figure 61. SAMEA DTaP and Tdap Vaccines Revenue Share by Type (2021-2032) Figure 62. SAMEA DTaP and Tdap Vaccines Sales Share by Type (2021-2032) Figure 63. SAMEA DTaP and Tdap Vaccines Revenue Share by Application (2021-2032) Figure 64. SAMEA DTaP and Tdap Vaccines Sales Share by Application (2021-2032) Figure 65. SAMEA DTaP and Tdap Vaccines Revenue Share by Country (2021-2032) Figure 66. SAMEA DTaP and Tdap Vaccines Sales Share by Country (2021-2032) Figure 67. DTaP and Tdap Vaccines Value Chain Figure 68. Manufacturing Cost Structure Figure 69. DTaP and Tdap Vaccines Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Tdap
  • DTaP
  • Td
Applications
  • Adult
  • Pediatric
Companies covered
  • Johnson & Johnson
  • Novartis AG
  • Lanzhou Institute of Biological Products Co., Ltd
  • Pfizer Inc
  • GlaxoSmithKline
  • AstraZeneca
  • Seqirus
  • Sanofi Pasteur
  • Protein Sciences Corporation
  • Merck Sharp & Dohme Corp
  • Emergent BioSolutions Inc
  • Astellas Pharma US, Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 DTaP and Tdap Vaccines Market by Type
  3. 1.2.1 Global DTaP and Tdap Vaccines Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Tdap
  5. 1.2.3 DTaP
  6. 1.2.4 Td
  7. 1.3 DTaP and Tdap Vaccines Market by Application
  8. 1.3.1 Global DTaP and Tdap Vaccines Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Adult
  10. 1.3.3 Pediatric
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 DTaP and Tdap Vaccines Market Dynamics
  1. 2.1 DTaP and Tdap Vaccines Industry Trends
  2. 2.2 DTaP and Tdap Vaccines Industry Drivers
  3. 2.3 DTaP and Tdap Vaccines Industry Opportunities and Challenges
  4. 2.4 DTaP and Tdap Vaccines Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global DTaP and Tdap Vaccines Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global DTaP and Tdap Vaccines Revenue by Region
  3. 3.2.1 Global DTaP and Tdap Vaccines Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global DTaP and Tdap Vaccines Revenue by Region (2021-2026)
  5. 3.2.3 Global DTaP and Tdap Vaccines Revenue by Region (2027-2032)
  6. 3.2.4 Global DTaP and Tdap Vaccines Revenue Market Share by Region (2021-2032)
  7. 3.3 Global DTaP and Tdap Vaccines Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global DTaP and Tdap Vaccines Sales by Region
  9. 3.4.1 Global DTaP and Tdap Vaccines Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global DTaP and Tdap Vaccines Sales by Region (2021-2026)
  11. 3.4.3 Global DTaP and Tdap Vaccines Sales by Region (2027-2032)
  12. 3.4.4 Global DTaP and Tdap Vaccines Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global DTaP and Tdap Vaccines Revenue by Manufacturers
  2. 4.1.1 Global DTaP and Tdap Vaccines Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global DTaP and Tdap Vaccines Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global DTaP and Tdap Vaccines Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global DTaP and Tdap Vaccines Sales by Manufacturers
  6. 4.2.1 Global DTaP and Tdap Vaccines Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global DTaP and Tdap Vaccines Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global DTaP and Tdap Vaccines Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global DTaP and Tdap Vaccines Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global DTaP and Tdap Vaccines Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global DTaP and Tdap Vaccines Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global DTaP and Tdap Vaccines Manufacturers, Product Type & Application
  13. 4.7 Global DTaP and Tdap Vaccines Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global DTaP and Tdap Vaccines Market CR5 and HHI
  16. 4.8.2 2025 DTaP and Tdap Vaccines Tier 1, Tier 2, and Tier 3
5 DTaP and Tdap Vaccines Market by Type
  1. 5.1 Global DTaP and Tdap Vaccines Revenue by Type
  2. 5.1.1 Global DTaP and Tdap Vaccines Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global DTaP and Tdap Vaccines Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global DTaP and Tdap Vaccines Revenue Market Share by Type (2021-2032)
  5. 5.2 Global DTaP and Tdap Vaccines Sales by Type
  6. 5.2.1 Global DTaP and Tdap Vaccines Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global DTaP and Tdap Vaccines Sales by Type (2021-2032) & (W Units)
  8. 5.2.3 Global DTaP and Tdap Vaccines Sales Market Share by Type (2021-2032)
  9. 5.3 Global DTaP and Tdap Vaccines Price by Type
6 DTaP and Tdap Vaccines Market by Application
  1. 6.1 Global DTaP and Tdap Vaccines Revenue by Application
  2. 6.1.1 Global DTaP and Tdap Vaccines Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global DTaP and Tdap Vaccines Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global DTaP and Tdap Vaccines Revenue Market Share by Application (2021-2032)
  5. 6.2 Global DTaP and Tdap Vaccines Sales by Application
  6. 6.2.1 Global DTaP and Tdap Vaccines Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global DTaP and Tdap Vaccines Sales by Application (2021-2032) & (W Units)
  8. 6.2.3 Global DTaP and Tdap Vaccines Sales Market Share by Application (2021-2032)
  9. 6.3 Global DTaP and Tdap Vaccines Price by Application
7 Company Profiles
  1. 7.1 Johnson & Johnson
  2. 7.1.1 Johnson & Johnson Company Information
  3. 7.1.2 Johnson & Johnson Business Overview
  4. 7.1.3 Johnson & Johnson DTaP and Tdap Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Johnson & Johnson DTaP and Tdap Vaccines Product Portfolio
  6. 7.1.5 Johnson & Johnson Recent Developments
  7. 7.2 Novartis AG
  8. 7.2.1 Novartis AG Company Information
  9. 7.2.2 Novartis AG Business Overview
  10. 7.2.3 Novartis AG DTaP and Tdap Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Novartis AG DTaP and Tdap Vaccines Product Portfolio
  12. 7.2.5 Novartis AG Recent Developments
  13. 7.3 Lanzhou Institute of Biological Products Co., Ltd
  14. 7.3.1 Lanzhou Institute of Biological Products Co., Ltd Company Information
  15. 7.3.2 Lanzhou Institute of Biological Products Co., Ltd Business Overview
  16. 7.3.3 Lanzhou Institute of Biological Products Co., Ltd DTaP and Tdap Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Lanzhou Institute of Biological Products Co., Ltd DTaP and Tdap Vaccines Product Portfolio
  18. 7.3.5 Lanzhou Institute of Biological Products Co., Ltd Recent Developments
  19. 7.4 Pfizer Inc
  20. 7.4.1 Pfizer Inc Company Information
  21. 7.4.2 Pfizer Inc Business Overview
  22. 7.4.3 Pfizer Inc DTaP and Tdap Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Pfizer Inc DTaP and Tdap Vaccines Product Portfolio
  24. 7.4.5 Pfizer Inc Recent Developments
  25. 7.5 GlaxoSmithKline
  26. 7.5.1 GlaxoSmithKline Company Information
  27. 7.5.2 GlaxoSmithKline Business Overview
  28. 7.5.3 GlaxoSmithKline DTaP and Tdap Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 GlaxoSmithKline DTaP and Tdap Vaccines Product Portfolio
  30. 7.5.5 GlaxoSmithKline Recent Developments
  31. 7.6 AstraZeneca
  32. 7.6.1 AstraZeneca Company Information
  33. 7.6.2 AstraZeneca Business Overview
  34. 7.6.3 AstraZeneca DTaP and Tdap Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 AstraZeneca DTaP and Tdap Vaccines Product Portfolio
  36. 7.6.5 AstraZeneca Recent Developments
  37. 7.7 Seqirus
  38. 7.7.1 Seqirus Company Information
  39. 7.7.2 Seqirus Business Overview
  40. 7.7.3 Seqirus DTaP and Tdap Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Seqirus DTaP and Tdap Vaccines Product Portfolio
  42. 7.7.5 Seqirus Recent Developments
  43. 7.8 Sanofi Pasteur
  44. 7.8.1 Sanofi Pasteur Company Information
  45. 7.8.2 Sanofi Pasteur Business Overview
  46. 7.8.3 Sanofi Pasteur DTaP and Tdap Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Sanofi Pasteur DTaP and Tdap Vaccines Product Portfolio
  48. 7.8.5 Sanofi Pasteur Recent Developments
  49. 7.9 Protein Sciences Corporation
  50. 7.9.1 Protein Sciences Corporation Company Information
  51. 7.9.2 Protein Sciences Corporation Business Overview
  52. 7.9.3 Protein Sciences Corporation DTaP and Tdap Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Protein Sciences Corporation DTaP and Tdap Vaccines Product Portfolio
  54. 7.9.5 Protein Sciences Corporation Recent Developments
  55. 7.10 Merck Sharp & Dohme Corp
  56. 7.10.1 Merck Sharp & Dohme Corp Company Information
  57. 7.10.2 Merck Sharp & Dohme Corp Business Overview
  58. 7.10.3 Merck Sharp & Dohme Corp DTaP and Tdap Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Merck Sharp & Dohme Corp DTaP and Tdap Vaccines Product Portfolio
  60. 7.10.5 Merck Sharp & Dohme Corp Recent Developments
  61. 7.11 Emergent BioSolutions Inc
  62. 7.11.1 Emergent BioSolutions Inc Company Information
  63. 7.11.2 Emergent BioSolutions Inc Business Overview
  64. 7.11.3 Emergent BioSolutions Inc DTaP and Tdap Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Emergent BioSolutions Inc DTaP and Tdap Vaccines Product Portfolio
  66. 7.11.5 Emergent BioSolutions Inc Recent Developments
  67. 7.12 Astellas Pharma US, Inc
  68. 7.12.1 Astellas Pharma US, Inc Company Information
  69. 7.12.2 Astellas Pharma US, Inc Business Overview
  70. 7.12.3 Astellas Pharma US, Inc DTaP and Tdap Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Astellas Pharma US, Inc DTaP and Tdap Vaccines Product Portfolio
  72. 7.12.5 Astellas Pharma US, Inc Recent Developments
8 North America
  1. 8.1 North America DTaP and Tdap Vaccines Market Size by Type
  2. 8.1.1 North America DTaP and Tdap Vaccines Revenue by Type (2021-2032)
  3. 8.1.2 North America DTaP and Tdap Vaccines Sales by Type (2021-2032)
  4. 8.1.3 North America DTaP and Tdap Vaccines Price by Type (2021-2032)
  5. 8.2 North America DTaP and Tdap Vaccines Market Size by Application
  6. 8.2.1 North America DTaP and Tdap Vaccines Revenue by Application (2021-2032)
  7. 8.2.2 North America DTaP and Tdap Vaccines Sales by Application (2021-2032)
  8. 8.2.3 North America DTaP and Tdap Vaccines Price by Application (2021-2032)
  9. 8.3 North America DTaP and Tdap Vaccines Market Size by Country
  10. 8.3.1 North America DTaP and Tdap Vaccines Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America DTaP and Tdap Vaccines Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America DTaP and Tdap Vaccines Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
9 Europe
  1. 9.1 Europe DTaP and Tdap Vaccines Market Size by Type
  2. 9.1.1 Europe DTaP and Tdap Vaccines Revenue by Type (2021-2032)
  3. 9.1.2 Europe DTaP and Tdap Vaccines Sales by Type (2021-2032)
  4. 9.1.3 Europe DTaP and Tdap Vaccines Price by Type (2021-2032)
  5. 9.2 Europe DTaP and Tdap Vaccines Market Size by Application
  6. 9.2.1 Europe DTaP and Tdap Vaccines Revenue by Application (2021-2032)
  7. 9.2.2 Europe DTaP and Tdap Vaccines Sales by Application (2021-2032)
  8. 9.2.3 Europe DTaP and Tdap Vaccines Price by Application (2021-2032)
  9. 9.3 Europe DTaP and Tdap Vaccines Market Size by Country
  10. 9.3.1 Europe DTaP and Tdap Vaccines Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe DTaP and Tdap Vaccines Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe DTaP and Tdap Vaccines Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Netherlands
  18. 9.3.9 Nordic Countries
10 China
  1. 10.1 China DTaP and Tdap Vaccines Market Size by Type
  2. 10.1.1 China DTaP and Tdap Vaccines Revenue by Type (2021-2032)
  3. 10.1.2 China DTaP and Tdap Vaccines Sales by Type (2021-2032)
  4. 10.1.3 China DTaP and Tdap Vaccines Price by Type (2021-2032)
  5. 10.2 China DTaP and Tdap Vaccines Market Size by Application
  6. 10.2.1 China DTaP and Tdap Vaccines Revenue by Application (2021-2032)
  7. 10.2.2 China DTaP and Tdap Vaccines Sales by Application (2021-2032)
  8. 10.2.3 China DTaP and Tdap Vaccines Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia DTaP and Tdap Vaccines Market Size by Type
  2. 11.1.1 Asia DTaP and Tdap Vaccines Revenue by Type (2021-2032)
  3. 11.1.2 Asia DTaP and Tdap Vaccines Sales by Type (2021-2032)
  4. 11.1.3 Asia DTaP and Tdap Vaccines Price by Type (2021-2032)
  5. 11.2 Asia DTaP and Tdap Vaccines Market Size by Application
  6. 11.2.1 Asia DTaP and Tdap Vaccines Revenue by Application (2021-2032)
  7. 11.2.2 Asia DTaP and Tdap Vaccines Sales by Application (2021-2032)
  8. 11.2.3 Asia DTaP and Tdap Vaccines Price by Application (2021-2032)
  9. 11.3 Asia DTaP and Tdap Vaccines Market Size by Country
  10. 11.3.1 Asia DTaP and Tdap Vaccines Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia DTaP and Tdap Vaccines Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia DTaP and Tdap Vaccines Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA DTaP and Tdap Vaccines Market Size by Type
  2. 12.1.1 SAMEA DTaP and Tdap Vaccines Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA DTaP and Tdap Vaccines Sales by Type (2021-2032)
  4. 12.1.3 SAMEA DTaP and Tdap Vaccines Price by Type (2021-2032)
  5. 12.2 SAMEA DTaP and Tdap Vaccines Market Size by Application
  6. 12.2.1 SAMEA DTaP and Tdap Vaccines Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA DTaP and Tdap Vaccines Sales by Application (2021-2032)
  8. 12.2.3 SAMEA DTaP and Tdap Vaccines Price by Application (2021-2032)
  9. 12.3 SAMEA DTaP and Tdap Vaccines Market Size by Country
  10. 12.3.1 SAMEA DTaP and Tdap Vaccines Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA DTaP and Tdap Vaccines Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA DTaP and Tdap Vaccines Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 DTaP and Tdap Vaccines Value Chain Analysis
  2. 13.1.1 DTaP and Tdap Vaccines Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 DTaP and Tdap Vaccines Production Mode & Process
  6. 13.2 DTaP and Tdap Vaccines Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 DTaP and Tdap Vaccines Distributors
  9. 13.2.3 DTaP and Tdap Vaccines Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst